Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1239 Results

Title
Intervention Indication Therapeutic Area Year Actions
Pembrolizumab for treatment of solid tumours – second line Pembrolizumab (Keytruda; MK-3475) Solid tumours Haematological Cancer and Lymphomas , Oncology 2021 View  |  Download
Pembrolizumab in addition to chemotherapy for advanced or metastatic urothelial cancer - first line Pembrolizumab (Keytruda; MK-3475) Urothelial cancer Urological Cancer 2018 View  |  Download
Pembrolizumab in addition to Chemotherapy for Locally Advanced, Non-Metastatic Triple Negative Breast Cancer – neoadjuvant, first line Pembrolizumab (Keytruda; MK-3475) Breast cancer Breast Cancer 2018 View  |  Download
Pembrolizumab in addition to chemotherapy for locally recurrent, inoperable or metastatic triple-negative breast cancer - first line Pembrolizumab (Keytruda; MK-3475) Breast cancer Breast Cancer 2018 View  |  Download
Pembrolizumab in addition to chemotherapy for perioperative treatment of gastric or gastro-oesophageal junction adenocarcinoma FLOT , Pembrolizumab (Keytruda; MK-3475) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2019 View  |  Download
Pembrolizumab in addition to cisplatin and fluorouracil for recurrent locally advanced or metastatic oesophageal cancer – First-line 5-Fluorouracil , Cisplatin (Platinol) , Pembrolizumab (Keytruda; MK-3475) Oesophageal cancer Head and Neck Cancer 2019 View  |  Download
Pembrolizumab in addition to docetaxel for chemotherapy-naive metastatic castration-resistant prostate cancer – second line Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Pembrolizumab (Keytruda; MK-3475) Prostate cancer Male Reproductive Cancer 2020 View  |  Download
Pembrolizumab in addition to lenvatinib for PD-L1 positive (at least 1%) non-small-cell lung cancer – first line Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Pembrolizumab in addition to platinum therapy and radiation for unresectable locally advanced head and neck squamous cell carcinoma Cisplatin (Platinol) , Pembrolizumab (Keytruda; MK-3475) Head and neck cancer Head and Neck Cancer 2019 View  |  Download
Pembrolizumab in addition to platinumpemetrexed chemotherapy for metastatic EGRF mutant non-squamous non-small-cell lung cancer – second line Pembrolizumab (Keytruda; MK-3475) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
1 2 81 82 83 84 85 123 124
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications